NAS:AVEO (USA) Also trade in: Germany UK

AVEO Pharmaceuticals Inc

$ 0.7 -0.01 (-1.56%)
Volume: 1,449,809 Avg Vol (1m): 6,672,245
Market Cap $: 112.50 Mil Enterprise Value $: 108.22 Mil
P/E (TTM): 0.00 P/B: 0.00
Earnings Power Value -16.1
Net Current Asset Value -0.14
Tangible Book -0.14
Projected FCF -2.98
Median P/S Value 0.3
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 2/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 1.22
Cash-To-Debt ranked lower than
80.71% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
AVEO: 1.22
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.97, Med: 3.1, Max: 11.08
Current: 1.22
0.97
11.08
Equity-to-Asset -0.70
Equity-to-Asset ranked lower than
98.56% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
AVEO: -0.7
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -3.21, Med: 0.34, Max: 0.79
Current: -0.7
-3.21
0.79
Debt-to-Equity -1.03
Debt-to-Equity ranked lower than
100.00% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
AVEO: -1.03
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -7.28, Med: 0.19, Max: 3.92
Current: -1.03
-7.28
3.92
Debt-to-EBITDA 2.97
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
AVEO: 2.97
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -6.07, Med: -0.45, Max: 2.97
Current: 2.97
-6.07
2.97
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -28.53
DISTRESS
GREY
SAFE
Beneish M-Score 6.86
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 9.1%

Profitability & Growth : 2/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -445.98
Operating Margin ranked lower than
64.90% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
AVEO: -445.98
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -7415.85, Med: -283.22, Max: 20.59
Current: -445.98
-7415.85
20.59
Net Margin % 70.30
Net Margin ranked lower than
67.30% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
AVEO: 70.3
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -8277.57, Med: -251.91, Max: 70.3
Current: 70.3
-8277.57
70.3
ROA % 15.10
ROA ranked lower than
74.91% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
AVEO: 15.1
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -167.84, Med: -52.18, Max: 15.1
Current: 15.1
-167.84
15.1
3-Year Total Revenue Growth Rate -34.20
3-Year Revenue Growth Rate ranked lower than
79.72% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
AVEO: -50.7
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -75.7, Med: -40.8, Max: 12.9
Current: -50.7
-75.7
12.9
3-Year Total EBITDA Growth Rate 0.10
3-Year EBITDA Growth Rate ranked higher than
77.93% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
AVEO: 25
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: 25, Max: 71.6
Current: 25
0
71.6
3-Year EPS w/o NRI Growth Rate 11.10
3-Year EPS w/o NRI Growth Rate ranked higher than
63.04% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
AVEO: 11.1
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 11.1, Max: 54.2
Current: 11.1
0
54.2

» AVEO's 30-Y Financials

Financials (Next Earnings Date: 2019-08-07)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:AVEO

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:APTX NAS:CKPT NAS:CRVS XTAE:CBI WBO:MARI NAS:SURF NAS:ETON XKRX:060590 NAS:MBIO NAS:ALNA XKRX:185490 NAS:SLGL OTCPK:RCAR LSE:TILS ROCO:6497 XKRX:046210 LSE:RENE TSE:2385 TSE:4557 NAS:EVFM
Traded in other countries VPA.Germany 0HJQ.UK
Address One Broadway, 14th Floor, Cambridge, MA, USA, 02142
AVEO Pharmaceuticals Inc operates as a biopharmaceutical company, which is engaged in the advancement of therapeutics for oncology and other areas of unmet medical need. The company views its operations and manages its business in the US. The firm offers products such as Tivozanib, Ficlatuzmab, AV-203, AV-380, and AV-353. Tivozanib is designed to optimize vascular endothelial growth factor blockade while minimizing off-target toxicities, Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity, AV-380, a humanized inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension.

Ratios

Current vs industry vs history
PS Ratio 15.56
PS Ratio ranked lower than
73.42% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
AVEO: 15.56
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.64, Med: 6.62, Max: 101.36
Current: 15.56
0.64
101.36
EV-to-EBIT 16.70
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
AVEO: 16.7
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -104.5, Med: -1.9, Max: 22.17
Current: 16.7
-104.5
22.17
EV-to-EBITDA 16.70
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
AVEO: 16.7
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -104.5, Med: -2, Max: 22.17
Current: 16.7
-104.5
22.17
EV-to-Revenue 18.05
EV-to-Revenue ranked lower than
69.26% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
AVEO: 18.05
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -12.2, Med: 7.4, Max: 99.7
Current: 18.05
-12.2
99.7
Current Ratio 1.39
Current Ratio ranked lower than
87.43% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
AVEO: 1.39
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.1, Med: 3.04, Max: 9.47
Current: 1.39
1.1
9.47
Quick Ratio 1.39
Quick Ratio ranked lower than
83.33% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
AVEO: 1.39
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.1, Med: 3.04, Max: 9.47
Current: 1.39
1.1
9.47
Days Sales Outstanding 156.56
Days Sales Outstanding ranked higher than
56.14% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
AVEO: 156.56
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 3.19, Med: 68.1, Max: 390.8
Current: 156.56
3.19
390.8

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -31.00
3-Year Share Buyback Rate ranked lower than
75.15% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
AVEO: -31
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -199.7, Med: -13.9, Max: -6.5
Current: -31
-199.7
-6.5

Valuation & Return

Current vs industry vs history
Price-to-Median-PS-Value 2.33
Price-to-Median-PS-Value ranked lower than
95.72% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
AVEO: 2.33
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.11, Med: 1.35, Max: 14.39
Current: 2.33
0.11
14.39
Earnings Yield (Joel Greenblatt) % 5.97
Earnings Yield (Greenblatt) ranked lower than
51.71% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
AVEO: 5.97
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -105714.2, Med: -24.6, Max: 48140
Current: 5.97
-105714.2
48140

More Statistics

Revenue (TTM) (Mil) $ 5.99
EPS (TTM) $ -0.33
Beta 1.16
Volatility % 102.85
52-Week Range $ 0.49 - 3.59
Shares Outstanding (Mil) 160.74

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA Y
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA N
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N